FDA probes Roche, Novartis meds

fda

The transplant drug probe is widening. FDA says it's identified 16 cases of an often-fatal neurological disease among patients taking Roche's CellCept drug, used to prevent organ rejection. The agency will review the reports and work on new labeling for the med over the next couple of months; in the meantime, FDA is warning doctors and patients to look out for neurological symptoms. The agency also is looking at similar risks with Myfortic, a drug made by Novartis that has the same active ingredient, though it hasn't received any reports of the disease in those patients.

You'll recall that Roche alerted FDA to the issue in November after receiving reports of progressive multifocal leukoencephalopathy, which attacks the brain and central nervous system; the disease is usually fatal, and survivors are often permanently disabled. Roche independently confirmed 10 cases of the disease in CellCept patients. Some 500,000 patients worldwide have used the drug, however. European regulators have already added cautionary language to the drug's label; Roche has submitted new labeling to the FDA, but the agency is still reviewing it.

ALSO: Genzyme is recalling more than 100,000 vials of Thymoglobulin, a kidney transplant drug, because of a manufacturing problem; no safety or efficacy problems have been found, however. Report

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Related Articles:
Roche's CellCept linked to birth defects. Roche report
Aspreva, Roche put CellCept on ice. CellCept report
Aspreva's CellCept fails late-stage superiority study. Aspreva report

Read more on

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.